Abstract: Objective CD38 is an effective target for clinical treatment of multiple myeloma. Due to the expression of CD38 on erythrocyte membrane, it combines with CD38 monoclonal antibody, which interferes with the compatibility test in pretransfusion and affects the safety in blood transfusion. Therefore, this study intends to establish a new method to solve the interference of anti-CD38 monoclonal antibody in the compatibility test. Methods Molp8 cell lines with high expression of CD38 were screened by database and flow cytometry, and then the method of removing interference by Molp8 cell adsorption was established to optimize the amount of cells and adsorption time. Antibody screening was performed by gel method to verify whether cell adsorption affected the detection of irregular antibodies and blood group antibodies. Finally, the cells were fixed with 4% paraformaldehyde to explore the effect of Molp8 cell line preservation time on the elimination of interference. Results flow cytometry showed that CD38 was highly expressed on Molp8 cells. The analysis of antibody screening by gel method showed that 30 μL of clinical samples incubated with 2×10⁶ Molp8 cells at 37 ℃ for 5 min could effectively eliminate the interference, and did not affect the detection of anti-D, anti-K, anti Fy^b and anti Jk^a antibodies in irregular antibodies. Molp8 cells were preserved in 4% paraformaldehyde for 14 days, and the interference elimination effect remains well. Conclusion Molp8 cells were used for the first time to solve the interference of anti-CD38 monoclonal antibody in the compatibility test before blood transfusion. Molp8 cells are easy to prepare and can also be stored for a short time as a reagent. The method is simple and fast, and has a certain potential for clinical application.

Key words: Multiple myeloma, Compatibility test pretransfusion, CD38 monoclonal antibody, Molp8 cells